# A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH

> **NCT02855892** · PHASE2 · COMPLETED · sponsor: **GemVax & Kael** · enrollment: 161 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia (BPH)

## Interventions

- **OTHER:** Placebo
- **DRUG:** GV1001

## Key facts

- **NCT ID:** NCT02855892
- **Lead sponsor:** GemVax & Kael
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2022-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02855892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02855892, "A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02855892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*